Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2004 2
2005 2
2006 2
2007 4
2008 1
2009 3
2010 1
2017 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries.
Antiretroviral Therapy Cohort Collaboration; Zwahlen M, Harris R, May M, Hogg R, Costagliola D, de Wolf F, Gill J, Fätkenheuer G, Lewden C, Saag M, Staszewski S, d'Arminio Monforte A, Casabona J, Lampe F, Justice A, von Wyl V, Egger M. Antiretroviral Therapy Cohort Collaboration, et al. Int J Epidemiol. 2009 Dec;38(6):1624-33. doi: 10.1093/ije/dyp306. Epub 2009 Oct 9. Int J Epidemiol. 2009. PMID: 19820106 Free PMC article.
The LOPSAQ study: 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapy.
Staszewski S, Babacan E, Stephan C, Haberl A, Carlebach A, Gute P, Klauke S, Hermschulte Y, Stuermer M, Dauer B; Frankfurt HIV Cohort. Staszewski S, et al. Among authors: dauer b. J Antimicrob Chemother. 2006 Nov;58(5):1024-30. doi: 10.1093/jac/dkl375. Epub 2006 Sep 6. J Antimicrob Chemother. 2006. PMID: 16956902 Clinical Trial.
The Protease Inhibitor Transfer Study (PROTRA 1): abacavir and efavirenz in combination as a substitute for a protease inhibitor in heavily pretreated HIV-1-infected patients with undetectable plasma viral load.
Bickel M, Rickerts V, Stephan C, Jacobi V, Rottmann C, Dauer B, Carlebach A, Thalhammer A, Miller V, Staszweski S. Bickel M, et al. Among authors: dauer b. HIV Med. 2005 May;6(3):179-84. doi: 10.1111/j.1468-1293.2005.00286.x. HIV Med. 2005. PMID: 15876284 Free article. Clinical Trial.
17 results